Cosmos Health (NASDAQ:COSM) CEO Purchases $45,162.50 in Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 90,325 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The stock was bought at an average cost of $0.50 per share, with a total value of $45,162.50. Following the purchase, the chief executive officer owned 8,182,120 shares in the company, valued at $4,091,060. The trade was a 1.12% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.

Grigorios Siokas also recently made the following trade(s):

• On Tuesday, January 20th, Grigorios Siokas purchased 353,321 shares of Cosmos Health stock. The shares were bought at an average price of $0.50 per share, with a total value of $176,660.50.
• On Wednesday, January 14th, Grigorios Siokas purchased 493,495 shares of Cosmos Health stock. The stock was purchased at an average price of $0.45 per share, with a total value of $222,072.75.
• On Monday, January 12th, Grigorios Siokas acquired 113,185 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.50 per share, for a total transaction of $56,592.50.
• On Thursday, January 8th, Grigorios Siokas bought 156,190 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.52 per share, with a total value of $81,218.80.
• On Wednesday, January 7th, Grigorios Siokas bought 124,880 shares of Cosmos Health stock. The stock was purchased at an average price of $0.52 per share, with a total value of $64,937.60.
• On Tuesday, January 6th, Grigorios Siokas purchased 133,953 shares of Cosmos Health stock. The shares were purchased at an average cost of $0.54 per share, for a total transaction of $72,334.62.
• On Friday, December 19th, Grigorios Siokas purchased 88,314 shares of Cosmos Health stock. The shares were purchased at an average price of $0.49 per share, for a total transaction of $43,273.86.
• On Monday, December 15th, Grigorios Siokas acquired 168,472 shares of Cosmos Health stock. The stock was purchased at an average cost of $0.42 per share, with a total value of $70,758.24.
• On Friday, November 28th, Grigorios Siokas bought 76,360 shares of Cosmos Health stock. The shares were acquired at an average price of $0.64 per share, for a total transaction of $48,870.40.
• On Tuesday, November 25th, Grigorios Siokas bought 55,732 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.63 per share, for a total transaction of $35,111.16.

Cosmos Health Price Performance

COSM stock opened at $0.49 on Thursday. The company has a market capitalization of $18.41 million, a P/E ratio of -0.66 and a beta of 5.37. The company has a fifty day moving average price of $0.52 and a 200-day moving average price of $0.73. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.84 and a current ratio of 0.99. Cosmos Health Inc. has a 52-week low of $0.28 and a 52-week high of $1.32.

Cosmos Health (NASDAQ:COSM) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The company had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. As a group, equities analysts expect that Cosmos Health Inc. will post -0.78 EPS for the current year.

Institutional Trading of Cosmos Health

A hedge fund recently raised its stake in Cosmos Health stock. Citadel Advisors LLC grew its holdings in shares of Cosmos Health Inc. (NASDAQ:COSM) by 133.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 225,507 shares of the company’s stock after acquiring an additional 128,776 shares during the period. Citadel Advisors LLC owned 0.65% of Cosmos Health worth $250,000 as of its most recent SEC filing. 12.61% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cosmos Health in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cosmos Health currently has a consensus rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.